Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GLTO NASDAQ:GRTX NASDAQ:LRMR NASDAQ:ORMP NASDAQ:TYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLTOGalecto$3.54+2.0%$3.18$2.01▼$16.07$4.67M1.3585,225 shs48,483 shsGRTXGalera Therapeutics$0.03+1.5%$0.03$0.02▼$0.14$2.04M1.8994,153 shs9,946 shsLRMRLarimar Therapeutics$3.42-1.8%$2.55$1.61▼$11.20$218.02M0.86840,614 shs476,069 shsORMPOramed Pharmaceuticals$2.15+1.4%$2.19$1.82▼$3.09$87.83M1.59141,093 shs14,249 shsTYMETyme Technologies$0.31$0.30$0.22▼$1.14$53.51M0.931.01 million shs2.68 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLTOGalecto+2.50%+1.01%+3.72%+50.22%-72.18%GRTXGalera Therapeutics-6.34%-9.52%+12.24%+10.37%-80.86%LRMRLarimar Therapeutics+0.58%+10.83%+19.59%+92.27%-61.99%ORMPOramed Pharmaceuticals-2.30%-2.93%-4.93%+0.47%-14.86%TYMETyme Technologies0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGLTOGalecto3.2685 of 5 stars3.55.00.00.00.71.71.3GRTXGalera Therapeutics0.309 of 5 stars0.03.00.00.00.61.70.0LRMRLarimar Therapeutics1.5577 of 5 stars3.61.00.00.01.11.70.0ORMPOramed Pharmaceuticals0.2984 of 5 stars0.03.00.00.00.00.80.6TYMETyme TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGLTOGalecto 3.00Buy$10.00182.49% UpsideGRTXGalera Therapeutics 0.00N/AN/AN/ALRMRLarimar Therapeutics 3.11Buy$18.50441.57% UpsideORMPOramed Pharmaceuticals 2.00HoldN/AN/ATYMETyme Technologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ORMP, GRTX, LRMR, GLTO, and TYME Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025LRMRLarimar TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/24/2025LRMRLarimar TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$17.00 ➝ $15.006/24/2025LRMRLarimar TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$26.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGLTOGalectoN/AN/AN/AN/A$10.99 per shareN/AGRTXGalera TherapeuticsN/AN/AN/AN/A($2.41) per shareN/ALRMRLarimar TherapeuticsN/AN/AN/AN/A$2.69 per shareN/AORMPOramed Pharmaceuticals$1.34M65.54N/AN/A$3.61 per share0.60TYMETyme TechnologiesN/AN/AN/AN/A$0.47 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGLTOGalecto-$21.44M-$15.53N/AN/AN/AN/A-98.27%-84.29%8/11/2025 (Estimated)GRTXGalera Therapeutics-$59.08M-$0.26N/A∞N/AN/AN/A-99.34%8/12/2025 (Estimated)LRMRLarimar Therapeutics-$80.60M-$1.49N/AN/AN/AN/A-52.48%-46.08%8/6/2025 (Estimated)ORMPOramed Pharmaceuticals-$19.06M-$0.44N/AN/AN/AN/A-11.34%-10.73%8/13/2025 (Estimated)TYMETyme Technologies-$23.63M-$0.14N/A∞N/AN/A-28.30%-26.21%N/ALatest ORMP, GRTX, LRMR, GLTO, and TYME EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025LRMRLarimar Therapeutics-$0.4877N/AN/AN/AN/AN/A5/15/2025Q1 2025ORMPOramed Pharmaceuticals-$0.03-$0.19-$0.16-$0.19N/A$2.00 million5/8/2025Q1 2025GLTOGalectoN/A-$1.92N/A-$1.92N/AN/A4/30/2025Q1 2025LRMRLarimar Therapeutics-$0.42-$0.46-$0.04-$0.46N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGLTOGalectoN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/ALRMRLarimar TherapeuticsN/AN/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/AN/ATYMETyme TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGLTOGalectoN/A9.629.62GRTXGalera TherapeuticsN/A9.749.74LRMRLarimar TherapeuticsN/A7.487.48ORMPOramed PharmaceuticalsN/A23.9423.94TYMETyme TechnologiesN/A14.0614.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGLTOGalecto14.20%GRTXGalera Therapeutics50.77%LRMRLarimar Therapeutics91.92%ORMPOramed Pharmaceuticals12.73%TYMETyme Technologies16.69%Insider OwnershipCompanyInsider OwnershipGLTOGalecto10.80%GRTXGalera Therapeutics12.90%LRMRLarimar Therapeutics4.50%ORMPOramed Pharmaceuticals13.70%TYMETyme Technologies16.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGLTOGalecto401.32 million1.18 millionOptionableGRTXGalera Therapeutics3075.46 million47.38 millionOptionableLRMRLarimar Therapeutics3064.03 million61.15 millionOptionableORMPOramed Pharmaceuticals1040.85 million35.25 millionOptionableTYMETyme Technologies17172.21 million143.10 millionOptionableORMP, GRTX, LRMR, GLTO, and TYME HeadlinesRecent News About These CompaniesTyme caps off a tough year for African startups with a unicorn crownJanuary 12, 2025 | independent.co.ugIHow Nubank’s Investment in Tyme Helps African StartupsJanuary 8, 2025 | fintechmagazine.comFNubank leads Tyme Group’s $250m Series D – valuing Tyme at $1.5bnJanuary 3, 2025 | intelligentcio.comITyme é avaliado em US$ 1,5 bi com apoio do Nubank, na ÁfricaDecember 18, 2024 | bloomberg.comBrazil’s Nubank invests $150 million in Tyme Group to expand digital banking offeringsDecember 18, 2024 | msn.comBrazilian bank Nubank makes a big R2.7bn investment in fintech Tyme GroupDecember 18, 2024 | msn.comSouth African Tyme Group Becomes Africa’s Latest Unicorn After $250M Series D FundingDecember 18, 2024 | msn.comTymeBank parent valued at $1.5-billion in latest fundraiseDecember 17, 2024 | techcentral.co.zaTBrazilian fintech giant invests in SA-born Tyme GroupDecember 17, 2024 | itnewsafrica.comIMulti-billion funding bolsters Tyme Group valuationDecember 17, 2024 | itweb.co.zaIBillionaire Patrice Motsepe’s Tyme worth $1.5 billion becomes Africa’s 9th unicornDecember 17, 2024 | nairametrics.comNTyme, Owners Of TymeBank And GoTyme, Raises R4.5 Billion In Funding Led By NYSE-Listed Brazilian FinTech NubankDecember 17, 2024 | techfinancials.co.zaTBrazilian fintech Nubank’s $150mn investment to give South Africa’s Tyme unicorn statusDecember 17, 2024 | ft.comAfrican digital bank Tyme raises $250M round led by Nubank at $1.5B valuationDecember 17, 2024 | msn.comDigital bank Tyme gains unicorn status with $250m Series D raiseDecember 17, 2024 | finance.yahoo.comNubank Announces Investment in Tyme Group, a Digital Bank With Operations in South Africa and the PhilippinesDecember 16, 2024 | businesswire.comBest Restaurants in Leominster, MassachusettsNovember 10, 2024 | thetechedvocate.orgTBest Restaurants in Quincy, IllinoisNovember 10, 2024 | thetechedvocate.orgTBest Restaurants in Peoria, IllinoisNovember 9, 2024 | thetechedvocate.orgTEden Green herb program named on TIME’s Best Inventions of 2024 listNovember 6, 2024 | producegrower.comPNew MarketBeat Followers Over TimeMedia Sentiment Over TimeORMP, GRTX, LRMR, GLTO, and TYME Company DescriptionsGalecto NASDAQ:GLTO$3.54 +0.07 (+2.02%) As of 03:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.Galera Therapeutics NASDAQ:GRTX$0.03 +0.00 (+1.50%) As of 02:43 PM EasternGalera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.Larimar Therapeutics NASDAQ:LRMR$3.42 -0.06 (-1.84%) As of 03:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.Oramed Pharmaceuticals NASDAQ:ORMP$2.15 +0.03 (+1.42%) As of 03:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.Tyme Technologies NASDAQ:TYMETyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
